SK9512003A3 - Subunit vaccines with A2 supermotifs - Google Patents

Subunit vaccines with A2 supermotifs Download PDF

Info

Publication number
SK9512003A3
SK9512003A3 SK951-2003A SK9512003A SK9512003A3 SK 9512003 A3 SK9512003 A3 SK 9512003A3 SK 9512003 A SK9512003 A SK 9512003A SK 9512003 A3 SK9512003 A3 SK 9512003A3
Authority
SK
Slovakia
Prior art keywords
peptide
epitope
hla
peptides
subsequence
Prior art date
Application number
SK951-2003A
Other languages
English (en)
Slovak (sk)
Inventor
John Sidney
Alessandro Sette
Howard M Grey
Scott Southwood
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Publication of SK9512003A3 publication Critical patent/SK9512003A3/sk

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SK951-2003A 2001-01-29 2002-01-29 Subunit vaccines with A2 supermotifs SK9512003A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26496901P 2001-01-29 2001-01-29
US09/935,476 US20040096445A1 (en) 1999-06-30 2001-08-22 Subunit vaccines with A2 supermotifs
PCT/US2002/002708 WO2002061435A2 (fr) 2001-01-29 2002-01-29 Vaccins purifies comportant des supermotifs structuraux a2

Publications (1)

Publication Number Publication Date
SK9512003A3 true SK9512003A3 (en) 2003-12-02

Family

ID=26950859

Family Applications (1)

Application Number Title Priority Date Filing Date
SK951-2003A SK9512003A3 (en) 2001-01-29 2002-01-29 Subunit vaccines with A2 supermotifs

Country Status (14)

Country Link
US (1) US20040096445A1 (fr)
EP (1) EP1368659A2 (fr)
JP (1) JP2005512016A (fr)
KR (1) KR20040052475A (fr)
CN (1) CN1653337A (fr)
AU (1) AU2002243730B2 (fr)
CA (1) CA2432995C (fr)
CZ (1) CZ20032054A3 (fr)
IL (1) IL156660A0 (fr)
MX (1) MXPA03006581A (fr)
NZ (1) NZ526860A (fr)
RU (1) RU2003126447A (fr)
SK (1) SK9512003A3 (fr)
WO (1) WO2002061435A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611713B2 (en) * 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US20110097352A9 (en) * 1992-01-29 2011-04-28 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
CA2685270C (fr) * 1998-05-13 2014-07-29 Pharmexa Inc. Vecteurs d'expression destines a stimuler une reponse immunitaire et procedes de leur utilisation
AU6226100A (en) * 1999-07-19 2001-04-24 Epimmune, Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US7462354B2 (en) * 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
US20040248113A1 (en) * 1999-12-28 2004-12-09 Alessandro Sette Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded thereby
WO2005012502A2 (fr) * 2003-03-28 2005-02-10 Idm Pharma, Inc. Procedes d'identification de variants optimaux d'epitopes peptidiques
JP5792630B2 (ja) 2009-01-28 2015-10-14 エピミューン，インコーポレイティド Ｐａｎ−ｄｒ結合ポリペプチドおよびその使用
AU2017367696A1 (en) * 2016-12-01 2019-06-20 Nant Holdings Ip, Llc Tumor antigenicity processing and presentation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1917970B1 (fr) * 1999-06-29 2011-06-15 Epimmune Inc. Peptides se fixant au Hla et leurs utilisations
US20040037843A1 (en) * 1999-12-21 2004-02-26 John Fikes Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions

Also Published As

Publication number Publication date
WO2002061435A2 (fr) 2002-08-08
IL156660A0 (en) 2004-01-04
CN1653337A (zh) 2005-08-10
CA2432995C (fr) 2011-07-26
JP2005512016A (ja) 2005-04-28
NZ526860A (en) 2007-03-30
AU2002243730B2 (en) 2007-07-12
US20040096445A1 (en) 2004-05-20
CZ20032054A3 (cs) 2003-12-17
EP1368659A2 (fr) 2003-12-10
CA2432995A1 (fr) 2002-08-08
MXPA03006581A (es) 2004-06-25
WO2002061435A3 (fr) 2003-07-10
KR20040052475A (ko) 2004-06-23
RU2003126447A (ru) 2005-02-27

Similar Documents

Publication Publication Date Title
JP3908271B2 (ja) Ｈｌａ−ａ２．１結合ペプチドおよびそれらの使用
EP1917970B1 (fr) Peptides se fixant au Hla et leurs utilisations
JP4776131B2 (ja) ヘテロクリティックアナログおよび関連方法
EP1911461B1 (fr) Peptides de liaisons HLA de classe I et II et leurs utilisations
JP4873810B2 (ja) ペプチドおよび核酸組成物を使用する、ヒト免疫不全ウイルス−１に対する細胞性免疫応答の誘導
JP6006265B2 (ja) Ｈｌａ−ｄｒ結合性ペプチドおよびそれらの使用
US20080260762A1 (en) HLA binding motifs and peptides and their uses
CA2248667C (fr) Peptides de fixation de hla-a2.1 et leurs utilisations
JP2003509465A (ja) ペプチドおよび核酸組成物を使用する、ｃ型肝炎ウイルスに対する細胞性免疫応答の誘導
EP0914142A1 (fr) Peptides presentant une affinite accrue de liaison avec des molecules
EP1263775A1 (fr) Peptides de liaison hla et utilisations de ces derniers
US20020177694A1 (en) Hla binding peptides and their uses
CA2432995C (fr) Peptides immunogeniques a restriction du supermotif hla-a2
US20040157273A1 (en) Subunit vaccines with a2 supermotifs
AU2002243730A1 (en) Subunit vaccines with A2 supermotifs
JP2004517609A (ja) Ｈｌａ−ａ２．１結合ペプチドおよびそれらの用途
EP1320377B1 (fr) Peptides de liaison aux hla et leurs utilisations
CA2421448A1 (fr) Peptides de fixation de hla et leurs utilisations
AU4754899A (en) HLA Binding peptides and their uses
JP2010001303A (ja) Ｈｌａ結合ペプチド及びその使用
KR20030036139A (ko) Ｈｌａ 결합 펩티드 및 이의 용도

Legal Events

Date Code Title Description
FC9A Refused patent application